6IGL image
Deposition Date 2018-09-25
Release Date 2018-11-21
Last Version Date 2023-11-22
Entry Detail
PDB ID:
6IGL
Title:
Crystal Structure of human ETB receptor in complex with IRL1620
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Endothelin receptor type B,Endolysin,Endothelin receptor type B
Gene (Uniprot):EDNRB
Mutations:R124Y,D154A,K270A,C1052T,C1095A,S342A,I381A,C396A,C400A,C405A
Chain IDs:A
Chain Length:498
Number of Molecules:1
Biological Source:Homo sapiens, Enterobacteria phage RB59
Polymer Type:polypeptide(L)
Molecule:IRL1620
Chain IDs:B
Chain Length:15
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Crystal structures of human ETBreceptor provide mechanistic insight into receptor activation and partial activation.
Nat Commun 9 4711 4711 (2018)
PMID: 30413709 DOI: 10.1038/s41467-018-07094-0

Abstact

Endothelin receptors (ETA and ETB) are class A GPCRs activated by vasoactive peptide endothelins, and are involved in blood pressure regulation. ETB-selective signalling induces vasorelaxation, and thus selective ETB agonists are expected to be utilized for improved anti-tumour drug delivery and neuroprotection. Here, we report the crystal structures of human ETB receptor in complex with ETB-selective agonist, endothelin-3 and an ETB-selective endothelin analogue IRL1620. The structure of the endothelin-3-bound receptor reveals that the disruption of water-mediated interactions between W6.48 and D2.50 is critical for receptor activation, while these hydrogen-bonding interactions are partially preserved in the IRL1620-bound structure. Consistently, functional analysis reveals the partial agonistic effect of IRL1620. The current findings clarify the detailed molecular mechanism for the coupling between the orthosteric pocket and the G-protein binding, and the partial agonistic effect of IRL1620, thus paving the way for the design of improved agonistic drugs targeting ETB.

Legend

Protein

Chemical

Disease

Primary Citation of related structures